Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — 29th Annual ROTH Conference 2017

22 slides from Sucampo Pharmaceuticals's conference presentation, Mar 13, 2017

  1. Slide 1: 29th Annual ROTH Conference: Sucampo Pharmaceuticals Corporate Update

    29 th Annual ROTH Conference March 13, 2017 Sucampo Pharmaceuticals, Inc. Corporate Update

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ

  3. Slide 3: Non-GAAP Metrics

    Non - GAAP Metrics 3 This presentation contains three financial metrics (Adjusted Net Income, EBITDA and Adjusted EBITDA) that are considered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metrics should be conside

  4. Slide 4: Investment Highlights

    Investment Highlights 4 • Global biopharmaceutical company with proven track record of successful product development and focus on innovative R&D • Business model supports financial strength with significant EBITDA and cash flow to fuel continued transformation – Sustained revenue growth from AMITIZ

  5. Slide 5: Secure, Advance, Transform

    Achieved Today 2017+ Revenue & Market Value Secure Advance Transform • Execute on pipeline opportunities − File LCM programs for regulatory approvals • BD strategy − Additional accretive transactions − Late stage development programs to strengthen, accelerate the pipeline − 4 transactions in 2016: −

  6. Slide 6: Constipation Market Overview

    Constipation Market Overview 6 Significant unmet need in efficacy, safety and patient satisfaction • U.S. constipation market is large and growing: ~$5B – Branded and generic Rx market: $4B / ~50M scripts/year (1) – OTC market: $800M / 23M units (30 - day supply) / year Opportunity to convert unsati

  7. Slide 7: AMITIZA: Broadest Label in Constipation Market

    AMITIZA: Broadest Label in Constipation Market 7 • Only product approved for all 3 constipation indications – Chronic Idiopathic Constipation (CIC): ~14% to 16% of adults globally – Irritable Bowel Syndrome - Constipation (IBS - C): ~15% of adults globally, 1/3 of which is IBS - C – Opioid Induced C

  8. Slide 8: AMITIZA Prescription Growth is Sustained

    8 U.S. TRx Scripts (1) 155 853 1,092 1,118 1,122 1,185 1,231 1,288 1,345 1,457 1,488 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 (Thousands) AMITIZA Prescription Growth is Sustained 2016 U.S. TRx YoY growth: 1 % • Growth highlights strong and enduring position in the constipation market •

  9. Slide 9: Competitive Overview

    Competitive Overview 9 Drug Rx or OTC Company Target Indication Commentary CIC IBS - C OIC Rx Sucampo (Marketed by Takeda) x All adults x Adult women x All adults • Long history of usage • Well - tolerated product with an established safety profile • No limitation on duration of use Rx Ironwood (Mar

  10. Slide 10: Blue-Chip Partnerships Provide Global Growth for AMITIZA

    Blue - Chip Partnerships Provide Global Growth for AMITIZA 10 Takeda is global commercialization partner (except Japan, China) • Royalty arrangement in North America (18% – 26%) plus 9.5% from product sales • 50% split of annual AMITIZA net sales revenue for North America beginning January 2021 • Re

  11. Slide 11: Recent Deals Have Unlocked Substantial AMITIZA Value

    Recent Deals Have Unlocked Substantial AMITIZA Value 11 • Sucampo’s acquisition of R - Tech Ueno closed on 12/03/2015 • Secured a larger portion of the global economics of AMITIZA and greater control over the manufacturing and supply chain for the product • Settlement agreements with Par Pharmaceuti

  12. Slide 12: New Pediatric Functional Constipation (PFC) Indication

    12 New Pediatric Functional Constipation (PFC) Indication • U.S. Prevalence: 18% of pediatric population (13.5M) • Unmet need: No FDA - approved therapies for PFC (black box warning for linaclotide; prucalopride failed in Phase 4); patients use OTC drugs off - label Phase 3 program in children 6 – 1

  13. Slide 13: AMITIZA Growth Secured

    AMITIZA Growth Secured x RTU acquisition increases AMITIZA revenue, captures add’l margin from vertically integrating mfg x Takeda extension • Net sales revenue split x Generic Agreements with Par & Dr. Reddy’s • Gross profit split x Underpenetrated markets with unsatisfied patients x Physician targ

  14. Slide 14: Product Pipeline

    14 Product Pipeline Sucampo Program Option Program Target First Indication Development Stage (s)NDA / MAA Filing Approval GI/Metabolic/ Inflamation AMITIZA CIC2 Pediatric functional constipation (6 - 17 yrs.) P3 2017 2018 Lubiprostone Sprinkle Formulation CIC2 Pediatric functional constipation 6 mos

  15. Slide 15: CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP

    CPP - 1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP 15 • Significant opportunity – Orphan indication in U.S. for familial adenomatous polyposis (FAP) • ~30K cases currently – No approved treatment options – Dire patient need • 100% risk of colon cancer • Progressive removal of colon/r

  16. Slide 16: Pipeline Progress: Upcoming Milestones

    Pipeline Progress: Upcoming Milestones 16 Product Event Expected Timing CPP - 1X/sulindac combination product Phase 3 futility analysis 1H17 AMITIZA File sNDA for PFC (6 – 17 years) 2H17 AMITIZA Top - line data from Phase 3 pivotal alternate formulation in adults AMITIZA File NDA for alternate formu

  17. Slide 17: Strong Financial Performance that Exceeded Guidance for Q4-16 and FY16

    Strong Financial Performance that Exceeded Guidance for Q4 - 16 and FY16 17 *A reconciliation of adjusted Net Income to GAAP Net Income and adjusted EBITDA to net income, the most directly comparable G AAP financial measure, is included in the Appendix. Balance Sheet End 12/31/16 Change End 12/31/15

  18. Slide 18: Strong Financial Performance, Continued

    Strong Financial Performance, Continued 18 *One - time $10.0 million milestone in the fourth quarter of 2016 related to the achievement of sales milestone from Mylan related to sales of AMITIZA in Japan. 2014 - 2015 are actual numbers. 2016 and 2017 are Sucampo Management’s guidance. $115 $153 $215

  19. Slide 19: Proven and Experienced Management Team

    Proven and Experienced Management Team Management Team with Considerable Experience in Product Development & Commercialization 19 Peter Greenleaf Chief Executive Officer Peter Kiener, D.Phil Chief Scientific Officer Peter Lichtlen, M.D., Ph.D. Chief Medical Officer Matthias Alder Executive Vice Pres

  20. Slide 20: Appendix

    Appendix

  21. Slide 21: Reconciliation for Non-GAAP Metrics

    Reconciliation for Non - GAAP Metrics 21 RECONCILIATION OF GAAP NET LOSS TO NON - GAAP NET INCOME (in thousands, except per share amounts) Three Months Ended Three Months Ended For the Year Ended For the Year Ended December 31, 2016 December 31, 2015 December 31, 2016 December 31, 2015 Adjusted Non

  22. Slide 22: Reconciliation for Non-GAAP Metrics

    Reconciliation for Non - GAAP Metrics 22 RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED EBITDA (in thousands, except per share amounts) Three Months Ended Three Months Ended For the Year Ended For the Year Ended December 31, 2016 December 31, 2015 December 31, 2016 December 31, 2015 GAAP Net I

Sucampo Pharmaceuticals — 29th Annual ROTH Conference 2017 on 6ix